

AMENDMENTS TO THE CLAIMS

WHAT IS CLAIMED IS:

1. (Currently Amended) A substantially pure polypeptide comprising
a fully human or humanized chimpanzee monoclonal antibody that binds or neutralizes dengue type 1, 2, 3, and/or 4 virus,
or comprising
a monoclonal antibody that binds the antigen to which monoclonal antibody 5H2 (~~ATCC Accession No. PTA-5662~~) binds, wherein said antibody 5H2 is produced by a plasmid deposited with the ATCC under Accession No. PTA-5662.
or comprising
a monoclonal antibody that binds the antigen to which monoclonal antibody 1A5 (~~ATCC Accession No. PTA-6265~~) binds wherein said antibody 1A5 is produced by a plasmid deposited with the ATCC under Accession No. PTA-6265.
2. (Original) The substantially pure polypeptide of Claim 1 wherein said antibody fragment comprises an Fd fragment.
3. (Original) The substantially pure polypeptide of Claim 1 wherein said antibody fragment comprises an Fab fragment.
4. (Original) The substantially pure polypeptide of Claim 1 wherein said antibody includes a heavy chain CDR3 region having the amino acid sequence of SEQ ID NO: 7, 23, 39, 55, 71, 87, 103, 119, 135, 151, 167, or 183.
5. (Original) The substantially pure polypeptide of Claim 4 wherein said antibody includes a heavy chain CDR2 region having the amino acid sequence of SEQ ID NO: 5 (when heavy chain CDR3 region is SEQ ID NO: 7), 21 (when heavy chain CDR3 region is SEQ ID NO: 23), 37 (when heavy chain CDR3 region is SEQ ID NO: 39), 53 (when heavy chain CDR3 region is SEQ ID NO: 55), 69 (when heavy chain CDR3 region is SEQ ID NO: 71), 85 (when heavy chain CDR3 region is SEQ ID NO: 87), 101 (when heavy chain CDR3 region is SEQ ID NO: 103), 117 (when heavy chain CDR3 region is SEQ ID NO: 119), 133 (when heavy chain CDR3 region is SEQ ID NO: 135), 149 (when heavy chain CDR3 region is SEQ ID NO: 151), 165 (when heavy chain CDR3 region is SEQ ID NO: 167), or 181 (when heavy chain CDR3 region is SEQ ID NO: 183).

6. (Original) The substantially pure polypeptide of Claim 5 wherein said antibody includes a heavy chain CDR1 region having the amino acid sequence of SEQ ID NO: 3 (when heavy chain CDR3 region is SEQ ID NO: 7), 19 (when heavy chain CDR3 region is SEQ ID NO: 23), 35 (when heavy chain CDR3 region is SEQ ID NO: 39), 51 (when heavy chain CDR3 region is SEQ ID NO: 55), 67 (when heavy chain CDR3 region is SEQ ID NO: 71), 83 (when heavy chain CDR3 region is SEQ ID NO: 87), 99 (when heavy chain CDR3 region is SEQ ID NO: 103), 115 (when heavy chain CDR3 region is SEQ ID NO: 119), 131 (when heavy chain CDR3 region is SEQ ID NO: 135), 147 (when heavy chain CDR3 region is SEQ ID NO: 151), 163 (when heavy chain CDR3 region is SEQ ID NO: 167), or 179 (when heavy chain CDR3 region is SEQ ID NO: 183).

7. (Original) The substantially pure polypeptide of Claim 4 wherein said antibody includes a heavy chain Fd region including the amino acid sequence of SEQ ID NO: 1 (when heavy chain CDR3 region is SEQ ID NO: 7), 17 (when heavy chain CDR3 region is SEQ ID NO: 23), 33 (when heavy chain CDR3 region is SEQ ID NO: 39), 49 (when heavy chain CDR3 region is SEQ ID NO: 55), 65 (when heavy chain CDR3 region is SEQ ID NO: 71), 81 (when heavy chain CDR3 region is SEQ ID NO: 87), 97 (when heavy chain CDR3 region is SEQ ID NO: 103), 113 (when heavy chain CDR3 region is SEQ ID NO: 119), 129 (when heavy chain CDR3 region is SEQ ID NO: 135), 145 (when heavy chain CDR3 region is SEQ ID NO: 151), 161 (when heavy chain CDR3 region is SEQ ID NO: 167), or 177 (when heavy chain CDR3 region is SEQ ID NO: 183).

8. (Original) The substantially pure polypeptide of Claim 4 wherein said antibody includes a light chain CDR3 region having the amino acid sequence of SEQ ID NO: 15 (when heavy chain CDR3 region is SEQ ID NO: 7), 31 (when heavy chain CDR3 region is SEQ ID NO: 23), 47 (when heavy chain CDR3 region is SEQ ID NO: 39), 63 (when heavy chain CDR3 region is SEQ ID NO: 55), 79 (when heavy chain CDR3 region is SEQ ID NO: 71), 95 (when heavy chain CDR3 region is SEQ ID NO: 87), 111 (when heavy chain CDR3 region is SEQ ID NO: 103), 127 (when heavy chain CDR3 region is SEQ ID NO: 119), 143 (when heavy chain CDR3 region is SEQ ID NO: 135), 159 (when heavy chain CDR3 region is SEQ ID NO: 151), 175 (when heavy chain CDR3 region is SEQ ID NO: 167), or 191 (when heavy chain CDR3 region is SEQ ID NO: 183).

9. (Original) The substantially pure polypeptide of Claim 8 wherein said antibody includes a light chain CDR2 region having the amino acid sequence of SEQ ID NO: 13 (when heavy chain CDR3 region is SEQ ID NO: 7), 29 (when heavy chain CDR3 region is SEQ ID NO: 23), 45 (when heavy chain CDR3 region is SEQ ID NO: 39), 61 (when heavy chain CDR3 region is SEQ ID NO: 55), 77 (when heavy chain CDR3 region is SEQ ID NO: 71), 93 (when heavy chain CDR3 region is SEQ ID NO: 87), 109 (when heavy chain CDR3 region is SEQ ID NO: 103), 125 (when heavy chain CDR3 region is SEQ ID NO: 119), 141 (when heavy chain CDR3 region is SEQ ID NO: 135), 157 (when heavy chain CDR3 region is SEQ ID NO: 151), 173 (when heavy chain CDR3 region is SEQ ID NO: 167), or 189 (when heavy chain CDR3 region is SEQ ID NO: 183).

10. (Original) The substantially pure polypeptide of Claim 9 wherein said antibody includes a light chain CDR1 region having the amino acid sequence of SEQ ID NO: 11 (when heavy chain CDR3 region is SEQ ID NO: 7), 27 (when heavy chain CDR3 region is SEQ ID NO: 23), 43 (when heavy chain CDR3 region is SEQ ID NO: 39), 59 (when heavy chain CDR3 region is SEQ ID NO: 55), 75 (when heavy chain CDR3 region is SEQ ID NO: 71), 91 (when heavy chain CDR3 region is SEQ ID NO: 87), 107 (when heavy chain CDR3 region is SEQ ID NO: 103), 123 (when heavy chain CDR3 region is SEQ ID NO: 119), 139 (when heavy chain CDR3 region is SEQ ID NO: 135), 155 (when heavy chain CDR3 region is SEQ ID NO: 151), 171 (when heavy chain CDR3 region is SEQ ID NO: 167), or 187 (when heavy chain CDR3 region is SEQ ID NO: 183).

11. (Original) The substantially pure polypeptide of Claim 4 wherein said antibody includes a light chain region including the amino acid sequence of SEQ ID NO: 9 (when heavy chain CDR3 region is SEQ ID NO: 7), 25 (when heavy chain CDR3 region is SEQ ID NO: 23), 41 (when heavy chain CDR3 region is SEQ ID NO: 39), 57 (when heavy chain CDR3 region is SEQ ID NO: 55), 73 (when heavy chain CDR3 region is SEQ ID NO: 71), 89 (when heavy chain CDR3 region is SEQ ID NO: 87), 105 (when heavy chain CDR3 region is SEQ ID NO: 103), 121 (when heavy chain CDR3 region is SEQ ID NO: 119), 137 (when heavy chain CDR3 region is SEQ ID NO: 135), 153 (when heavy chain CDR3 region is SEQ ID NO: 151), 169 (when heavy chain CDR3 region is SEQ ID NO: 167), or 185 (when heavy chain CDR3 region is SEQ ID NO: 183).

12. (Original) The substantially pure polypeptide of Claim 4 wherein said antibody includes a heavy chain Fd region including the CDR amino acid sequences of SEQ ID NO: 1 (when heavy chain CDR3 region is SEQ ID NO: 7), 17 (when heavy chain CDR3 region is SEQ ID NO: 23), 33 (when heavy chain CDR3 region is SEQ ID NO: 39), 49 (when heavy chain CDR3 region is SEQ ID NO: 55), 65 (when heavy chain CDR3 region is SEQ ID NO: 71), 81 (when heavy chain CDR3 region is SEQ ID NO: 87), 97 (when heavy chain CDR3 region is SEQ ID NO: 103), 113 (when heavy chain CDR3 region is SEQ ID NO: 119), 129 (when heavy chain CDR3 region is SEQ ID NO: 135), 145 (when heavy chain CDR3 region is SEQ ID NO: 151), 161 (when heavy chain CDR3 region is SEQ ID NO: 167), or 177 (when heavy chain CDR3 region is SEQ ID NO: 183).

13. (Original) The substantially pure polypeptide of Claim 12 wherein said antibody includes a light chain region including the CDR amino acid sequences of SEQ ID NO: 9 (when heavy chain CDR3 region is SEQ ID NO: 7), 25 (when heavy chain CDR3 region is SEQ ID NO: 23), 41 (when heavy chain CDR3 region is SEQ ID NO: 39), 57 (when heavy chain CDR3 region is SEQ ID NO: 55), 73 (when heavy chain CDR3 region is SEQ ID NO: 71), 89 (when heavy chain CDR3 region is SEQ ID NO: 87), 105 (when heavy chain CDR3 region is SEQ ID NO: 103), 121 (when heavy chain CDR3 region is SEQ ID NO: 119), 137 (when heavy chain CDR3 region is SEQ ID NO: 135), 153 (when heavy chain CDR3 region is SEQ ID NO: 151), 169 (when heavy chain CDR3 region is SEQ ID NO: 167), or 185 (when heavy chain CDR3 region is SEQ ID NO: 183).

14. (Original) An isolated nucleic acid comprising a nucleotide sequence encoding a polypeptide selected from the group consisting of the polypeptide of Claim 1, the polypeptide of Claim 2, the polypeptide of Claim 3, the polypeptide of Claim 4, the polypeptide of Claim 5, the polypeptide of Claim 6, the polypeptide of Claim 7, the polypeptide of Claim 8, the polypeptide of Claim 9, the polypeptide of Claim 10, the polypeptide of Claim 11, the polypeptide of Claim 12, and the polypeptide of Claim 13.

15. (Original) An isolated nucleic acid as in Claim 14, wherein said nucleic acid comprises a vector including a regulatory sequence operably joined to said nucleic acid.

16. (Original) A host cell including a vector comprising a nucleic acid of Claim 14.

17. (Original) A pharmaceutical preparation comprising

a pharmaceutically acceptable carrier; and

a substantially pure polypeptide selected from the group consisting of the polypeptide of Claim 1, the polypeptide of Claim 2, the polypeptide of Claim 3, the polypeptide of Claim 4, the polypeptide of Claim 5, the polypeptide of Claim 6, the polypeptide of Claim 7, the polypeptide of Claim 8, the polypeptide of Claim 9, the polypeptide of Claim 10, the polypeptide of Claim 11, the polypeptide of Claim 12, and the polypeptide of Claim 13.

18. (Original) A diagnostic preparation comprising
a pharmaceutically acceptable carrier; and

a substantially pure polypeptide selected from the group consisting of the polypeptide of Claim 1, the polypeptide of Claim 2, the polypeptide of Claim 3, the polypeptide of Claim 4, the polypeptide of Claim 5, the polypeptide of Claim 6, the polypeptide of Claim 7, the polypeptide of Claim 8, the polypeptide of Claim 9, the polypeptide of Claim 10, the polypeptide of Claim 11, the polypeptide of Claim 12, and the polypeptide of Claim 13.

19. (Original) A method for the treatment of dengue virus disease comprising administering to a patient a therapeutically effective amount of the pharmaceutical preparation of Claim 17.

20. (Original) A method for prophylaxis against dengue virus disease comprising administering to a patient a prophylactically effective amount of the pharmaceutical preparation of Claim 17.

21. (Original) A method for the diagnosis of dengue virus disease comprising administering to a patient an effective amount of the diagnostic preparation of Claim 18, and

detecting binding of the substantially pure polypeptide as a determination of the presence of dengue virus disease.

22. (Original) A method of detecting the presence of dengue virus in a biological sample comprising

contacting said sample with the diagnostic preparation of Claim 18, and

assaying binding of the substantially pure polypeptide as a determination of the presence of said dengue virus.

23. (Original) Humanized IgG1 5H2 plasmid deposited with ATCC as ATCC Accession No. PTA-5662.

24. (Original) Humanized IgG1 1A5 plasmid deposited with ATCC as ATCC Accession No. PTA-6265.

25. (Cancelled).

26. (New) An isolated humanized chimpanzee monoclonal antibody that neutralizes dengue virus.

27. (New) The isolated monoclonal antibody of Claim 26, wherein said antibody neutralizes dengue type 1 virus.

28. (New) The isolated monoclonal antibody of Claim 26, wherein said antibody neutralizes dengue type 2 virus.

29. (New) The isolated monoclonal antibody of Claim 26, wherein said antibody neutralizes dengue type 3 virus.

30. (New) The isolated monoclonal antibody of Claim 26, wherein said antibody neutralizes dengue type 4 virus.

31. (New) The isolated monoclonal antibody of Claim 26, wherein said monoclonal antibody comprises a chimpanzee variable region and a human constant region.

32. (New) The isolated monoclonal antibody of Claim 26, wherein said antibody is produced by a plasmid having ATCC Accession No. PTA-5662.

33. (New) The isolated monoclonal antibody of Claim 26, wherein said antibody is produced by a plasmid having ATCC Accession No. PTA-6265.